Product logins

Find logins to all Clarivate products below.


Location Location Location: How Shifting Procedural Site of Service Affects Competitive Strategy in the Orthopedic Device Industry

Patients surgically treated for orthopedic indications have a unique set of characteristics when compared with other surgical patients; critically, surgical treatment for these patients is often elective. This differentiating factor is one of many contributing drivers to the noticeable changing site of service for some orthopedic procedures; many orthopedic procedures are moving away from the traditional hospital setting and towards ambulatory surgical centers. As a key stakeholder, medical device firms have to come to grips with this changing landscape and demonstrate the strategic willingness to capitalize on this trend. In spite of the presence of many significant obstacles, including but not limited to challenges to reimbursement in the ASC setting, medical device manufacturers looking to benefit from this site of service shift must adapt their existing portfolios, make an effort to understand the reimbursement and demographic landscape relevant to ASCs, and adjust their pricing and marketing strategies to target ASCs. In so doing, as ASCs assume a more pivotal role in orthopedic care over time, orthopedic medical device companies taking these steps can better ready themselves to effectively compete in the increasingly entrenched orthopedic device market.

Related Market Assessment Reports

Report
Epilepsy – Unmet Need – Unmet Need – Dravet Syndrome (US/EU)
Dravet syndrome (DS) is a rare, severe, pediatric-onset genetic epileptic encephalopathy that typically emerges within the first year of life and is marked by developmental delays and multiple…
Report
Alzheimer’s Disease – Unmet Need – Unmet Need – Agitation in Alzheimer’s Disease (US/EU)
Agitation affects most Alzheimer’s disease (AD) patients and comprises a constellation of disruptive symptoms for patients and their families, which may contribute to nursing home placement…
Report
Breast Cancer – Unmet Need – Unmet Need – Metastatic HR-Positive / HER2-Negative Breast Cancer (US/EU)
The landscape of advanced HR-positive / HER2-negative breast cancer treatment is continually evolving. CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio)…
Report
Hepatitis B Virus – Geographic Focus: China – China In-Depth – Hepatitis B Virus
HBV is a major public health burden in China, with chronically infected individuals at a significantly increased risk of developing hepatic cirrhosis and hepatocellular carcinoma. Current treatment…
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Current Treatment: Physician Insights – B-Cell Non-Hodgkin’s Lymphoma (US)
Non-Hodgkin’s lymphoma (NHL) represents a diverse group of hematological malignancies broadly classified into indolent and aggressive subtypes. Patients with aggressive NHL—diffuse large B-cell…